<DOC>
	<DOCNO>NCT01285583</DOCNO>
	<brief_summary>The purpose assay ass safety TRO19622 330 mg QD add-on therapy riluzole 50 mg bid treatment patient suffer ALS , completion precede clinical trial ( TRO19622 CL E Q 1015-1 ) open label extension .</brief_summary>
	<brief_title>Safety Extension Study TRO19622 ALS</brief_title>
	<detailed_description>Entry patient safety study intend occur immediately patient finish participate precede efficacy study ( Protocol TRO19622 CL E Q 1015-1 ) . The Investigator explain patient nature open-label safety study , procedure , requirement restriction obtain write informed consent . Each patient treat olesoxime ( TRO19622 ) result double-blind trial become available maximum 15 month . Follow-up visit take place every 3 month ( +/- 2 week ) . Safety assessment perform visit ( every 3 month ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>Patients must complete 18month safety efficacy study TRO19622 Amyotrophic Lateral Sclerosis ( ALS ) patient treat riluzole ( Protocol TRO19622 CL E Q 10151 ) . Both investigator patient decide base previous good tolerance clinical ground whether participate openlabel extension . If patient antivitamin K doubleblind period , enter openlabel extension , coagulation test monitor exactly condition new anticoagulant treatment initiate dose antivitamin K adjust accordingly . Patients enrol prior safety efficacy study must : If female childbearing age potential , continue use adequate birth control method negative serum pregnancy test precede doubleblind protocol termination visit . Male female partner must agree use effective method birth control participation trial least 15 day last IMP dose . Both partner must use reliable method contraception 2 independent method . The following measure acceptable : Hormone contraceptive ( e.g . oral contraceptive comparable method ) , intrauterine device , condom spermicidal coat combination spermicidal cream , total abstinence sterilisation perform past . Be able follow investigator 's instruction able comply visit schedule visit requirement ; Sign write informed consent . Patients may participate study ongoing , unresolved , clinically significant medical problem ( include patient experience serious adverse event nonserious , medically significant adverse event precede safety efficacy study assess related study medication investigator ) judgment investigator would make unsafe patient participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Amyotrophoc Lateral Sclerosis</keyword>
	<keyword>TRO19622</keyword>
	<keyword>Olesoxime</keyword>
	<keyword>Trophos</keyword>
</DOC>